Molecular targets for COVID-19 drug development: Enlightening Nigerians about the pandemic and future treatment

There is little or no research initiated on enlightening Nigerians about the pathogenesis, targets for drug development and repositioning for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Coronavirus disease 2019 (COVID-19) is a viral infection causing symptoms like dry cough, sore throat, nasal congestion, tiredness, fever, loss of taste, and smell etc. The disease was first reported in Wuhan, China, in December 2019. The infection is caused by SARS-CoV-2, which is the third introduction of a highly pathogenic coronavirus into the human population. Coronaviruses are viruses with a positive RNA envelope assigned to α, β, γ, and δ genera. Moreover, SARS-CoV-2 belongs to the β genus. The four structural proteins of β coronavirus are membrane (M), envelope (E), spike (S), and nucleocapsid (N) protein, mediation of coronavirus host infection is established by spike (S) protein. Therefore, the search for drug development targets and repositioning of existing therapeutics is essential for fighting the present pandemic. It was reviewed that therapeutics targeting SARS-CoV-2 binding to ACE2 receptor, viral RNA synthesis and replication, 3CLpro, RdRp, and helicase will play a crucial role in the development of treatment for SARS-CoV-2 infection. Furthermore, the RdRp and spike protein of SARS-CoV-2 are the most promising targets for drug development and repositioning and vaccine development. Remdesivir combination with chloroquine/hydroxychloroquine are promising drug repositioning for the treatment of COVID-19, and mRNA-1273 targeting spike protein is the promising vaccine. However, as patient management and drug repositioning are taking place, it is imperative to identify other promising targets used by SARS-CoV-2 to establish infection, to develop novel therapeutics. •This study investigated molecular targets for drug repositioning, monoclonal antibody, mRNA vaccine and novel drug development.•Proteins associated with SARS-CoV-2 infection could be explored for drug and vaccine development.•Molecular Targets critical in SARS-CoV-2 replication and RNA synthesis are PLpro, 3CLpro, RdRp and Helicase.•Spike protein is one of the great targets for drug repositioning, monoclonal antibody, and vaccine development.•Also, virulence factors such as nsp1, nsp3c, and ORF7a can be explored for SARS-Cov-2 drug development.•Remdesivir targeting RdRp and chloroquine affecting spike protein activity are under clinical trial.•It is suggested that extensiv